Prevención integral del cáncer de cuello uterino

  1. José Antonio Vidart Aragón 1
  2. Javier Cortés 2
  1. 1 Real Academia Nacional de Medicina de España
  2. 2 Real Academia de Medicina de las Islas Baleares
Journal:
Anales de la Real Academia Nacional de Medicina

ISSN: 0034-0634

Year of publication: 2019

Issue: 136

Pages: 287-291

Type: Article

DOI: 10.32440/AR.2019.136.03.REV09 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Anales de la Real Academia Nacional de Medicina

Abstract

We review the evidence supporting the recommendation made by the World Health Organization aimed at the eradication of cervical cancer in the medium term through synergistic application with high coverage of vaccination against human papillomavirus and redesigned screening.

Bibliographic References

  • Zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW.: Attempts to detect virus-specific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int J Cancer. 1974; 13: 650-656.
  • Zur Hausen H.:Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184(1): 9-13
  • Walboomers JM, Jacobs MV, Manos MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
  • Ghebreyesus TA.: WHO Meeting. Genève. 19 de Mayo 2018.
  • Peng S, Frazer IH, Fernando GJ, Zhou J.: Papillomavirus virus-like particles can deliver CTL epitopes to the MHC class I pathway. Virology. 1989; 240: 147-157.
  • Vacunas Profilácticas frente al Virus del Papiloma Humano: Documento de Consenso de las Sociedades Científicas Españolas. 31 de Enero de 2007. J. Cortés Coordinador. SP.MSD Ediciones.
  • https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/CoberturasVacunacion/Tabla11.pdf Acceso 29 de Abril de 2019.
  • Departamentos Médicos de Merck y GlaxoSmithKline. Comunicación Personal.
  • Cortés J.: ¿Por qué no prescribes la vacuna VPH? En preparación.
  • http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000721/WC500024634.pdf. Acceso 2 de Mayo 2019.
  • http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003852/WC500189114.pdf. Acceso 3 de Mayo 2019.
  • Pollock KG.: Sustained cross-protection of the bivalent HPV vaccine.J Infect Dis. 2018; 10: 1515-1516.
  • World Health Organization: Weekly Epidemiological Report. Human Papillomavirus vaccine: WHO Position Paper May 2017.; 82: 241-268.
  • Palmer T.: Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. Br Med J 2019; 365 doi: https://doi.org/10.1136/bmj.l1161
  • Sakamoto M, Miyagi E, Sumi Y et al.: Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. J Infect Chemother. 2019 : S1341-321X(18)30302-7. doi: 10.1016/j.jiac.2019.02.012.
  • Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L.: Quadrivalent HPV vaccine effectiveness against highgrade cervical lesions by age at vaccination: A population-based study. Int J Cancer. 2016; 138: 2867-2874.
  • Cortés J.: Vacunatión and fake-news. Salut i Força. 2019; 391: 3.
  • Cortés J.: Estrategias de cribado del cáncer de cuello uterino. Prog Obstet Ginecol 2005; 48 Supl 1: 228 – 230.
  • Georgalis L, de Sanjosé S, Esnaola M, Bosch FX, M Diaz M.: Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis. Eur J Cancer Prev. 2016; 25: 430-439.
  • Cortés J, Bosch FX, Concha A, et al.: Spanish Cancer Association: Cervical Cancer Prevention Position Statement. Prog Obstet Ginecol.2019; 61: 510 – 544.
  • Papanicolaou GN, Traut HF.: The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med. 1997; 121: 211-214
  • Papanicolaou GN.: New Cancer Diagnosis. Third Race Betterment Conference. Battje Creek, Michigan, USA. 1928.
  • Christopherson WM, Parker JE, Drye JC.: Control of cervical cancer. Preliminary report on community program. JAMA. 1962; 182: 179-182.
  • Walton RJ.: Editorial: The task force on cervical cancer screening programs. Can Med Assoc J. 1976; 114(11): 981.
  • Cuzick J, Clavel C, Petry KU et al.: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095-1101.
  • Mayrand MH, Duarte-Franco E, Rodrigues I et al.: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579-1588.
  • van der Horst J, Siebers AG, Bulten J, Massuger LF, de Kok IM.: Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. Cancer Med. 2017; 6: 416-423.
  • Ronco G, Dillner J, Elfström KM et al for the International HPV screening working group: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383: 524-532.
  • Koliopoulos G, Nyaga VN, Santesso N et al.: Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017; Aug 10;8: CD008587.
  • Quinn M, Babb P, Jones J, Allen E.: Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. Br Med J. 1999; 318: 904-908.
  • Torné A, del Pino M, Cusidó M et al.: Guía de cribado del cáncer de cuello de útero en España. Prog Obstet Ginecol. 2014; 57 (Supl.1): 1-53.
  • Ibáñez R, Alejo M, Combalia N et al.: Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. Biomed Res Int. 2015; vol.2015: Article ID 605375. 9 pages.
  • https://boe.es/boe/dias/2019/04/27/pdfs/BOEA-2019-6277.pdf Acceso 30 de Abril de 2019.
  • Meijer CJ, Berkhof J, Castle PE et al.: Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009; 124: 516-520.
  • Hall MT, Simms KT, Lew JB et al.: The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019; 4: e19-e27.
Data source: Dialnet